COVID-19: A review of therapeutic strategies and vaccine candidates
The world is engulfed by one of the most widespread and significant public health crises in
decades as COVID-19 has become among the leading causes of death internationally. The …
decades as COVID-19 has become among the leading causes of death internationally. The …
Endothelium structure and function in kidney health and disease
N Jourde-Chiche, F Fakhouri, L Dou, J Bellien… - Nature Reviews …, 2019 - nature.com
The kidney harbours different types of endothelia, each with specific structural and functional
characteristics. The glomerular endothelium, which is highly fenestrated and covered by a …
characteristics. The glomerular endothelium, which is highly fenestrated and covered by a …
Molecules great and small: the complement system
DR Mathern, PS Heeger - … Journal of the American Society of …, 2015 - journals.lww.com
The complement cascade, traditionally considered an effector arm of innate immunity
required for host defense against pathogens, is now recognized as a crucial pathogenic …
required for host defense against pathogens, is now recognized as a crucial pathogenic …
Dynamics of complement activation in aHUS and how to monitor eculizumab therapy
M Noris, M Galbusera, S Gastoldi… - Blood, The Journal …, 2014 - ashpublications.org
Atypical hemolytic-uremic syndrome (aHUS) is associated with genetic complement
abnormalities/anti–complement factor H antibodies, which paved the way to treatment with …
abnormalities/anti–complement factor H antibodies, which paved the way to treatment with …
[HTML][HTML] Atypical hemolytic uremic syndrome
D Kavanagh, TH Goodship, A Richards - Seminars in nephrology, 2013 - Elsevier
Hemolytic uremic syndrome (HUS) is a triad of microangiopathic hemolytic anemia,
thrombocytopenia, and acute renal failure. The atypical form of HUS is a disease …
thrombocytopenia, and acute renal failure. The atypical form of HUS is a disease …
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
J Zuber, F Fakhouri, LT Roumenina, C Loirat… - Nature Reviews …, 2012 - nature.com
In the past decade, a large body of evidence has accumulated in support of the critical role
of dysregulation of the alternative complement pathway in atypical haemolytic uraemic …
of dysregulation of the alternative complement pathway in atypical haemolytic uraemic …
[HTML][HTML] Atypical hemolytic uremic syndrome
C Loirat, V Frémeaux-Bacchi - Orphanet journal of rare diseases, 2011 - Springer
Hemolytic uremic syndrome (HUS) is defined by the triad of mechanical hemolytic anemia,
thrombocytopenia and renal impairment. Atypical HUS (aHUS) defines non Shiga-toxin …
thrombocytopenia and renal impairment. Atypical HUS (aHUS) defines non Shiga-toxin …
Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: case series …
N Kello, L El Khoury, G Marder, R Furie… - Seminars in arthritis and …, 2019 - Elsevier
Introduction Thrombotic microangiopathy (TMA) is a life-threatening, albeit infrequent,
complication of systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS) …
complication of systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS) …
Haemolytic uraemic syndrome
D Karpman, S Loos, R Tati… - Journal of internal …, 2017 - Wiley Online Library
Haemolytic uraemic syndrome (HUS) is defined by the simultaneous occurrence of
nonimmune haemolytic anaemia, thrombocytopenia and acute renal failure. This leads to …
nonimmune haemolytic anaemia, thrombocytopenia and acute renal failure. This leads to …